Cargando…
Evaluation of the safety and efficacy of using human menstrual blood‐derived mesenchymal stromal cells in treating severe and critically ill COVID‐19 patients: An exploratory clinical trial
The coronavirus disease 2019 (COVID‐19), caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) was identified in December 2019 and has subsequently spread worldwide. Currently, there is no effective method to cure COVID‐19. Mesenchymal stromal cells (MSCs) may be able to effectively...
Autores principales: | Xu, Xiaowei, Jiang, Wanli, Chen, Lijun, Xu, Zhenyu, Zhang, Qiang, Zhu, Mengfei, Ye, Peng, Li, Hang, Yu, Liang, Zhou, Xiaoyang, Zhou, Chenliang, Chen, Xiaobei, Zheng, Xiaoqin, Xu, Kaijin, Cai, Hongliu, Zheng, Shufa, Jiang, Wubian, Wu, Xiaojun, Li, Dong, Chen, Lu, Luo, Qingqing, Wang, Yingyan, Qu, Jingjing, Li, Yifei, Zheng, Wendi, Jiang, Yingan, Tang, Lingling, Xiang, Charlie, Li, Lanjuan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7839959/ https://www.ncbi.nlm.nih.gov/pubmed/33634996 http://dx.doi.org/10.1002/ctm2.297 |
Ejemplares similares
-
Clinical study using mesenchymal stem cells for the treatment of patients with severe COVID-19
por: Tang, Lingling, et al.
Publicado: (2020) -
Human menstrual blood-derived stem cells mitigate bleomycin-induced pulmonary fibrosis through anti-apoptosis and anti-inflammatory effects
por: Chen, Xin, et al.
Publicado: (2020) -
Lack of Vertical Transmission of Severe Acute Respiratory Syndrome Coronavirus 2, China
por: Li, Yang, et al.
Publicado: (2020) -
Effect of artificial liver blood purification treatment on the survival of critical ill COVID‐19 patients
por: Dai, Xiahong, et al.
Publicado: (2021) -
Mesenchymal stem cell homing to improve therapeutic efficacy in liver disease
por: Yuan, Mengqin, et al.
Publicado: (2022)